Search the Newsreel

Press Release: Nano Dimension and Murchinson Announce Agreement to Reconstitute the Company's Board of Directors

Nano Dimension and Murchinson Ltd. have reached an agreement to reconstitute Nano Dimension's Board of Directors. The agreement includes the immediate appointment of two new independent directors proposed by Murchinson and a third independent director to be appointed mutually within 45 days. This resolution …

Sensient Technologies (SXT) Q2 2026 Preview: EPS Est. $1.03, Reports July 24

Sensient Technologies (SXT) is expected to report Q2 2026 earnings of $1.03 per share on revenue of $448.9 million, representing significant year-over-year growth. While analyst EPS estimates have seen a slight downward revision in the last 30 days, they are up over the 90-day …

Nano Dimension and activist investor Murchison complete overhaul to board; CEO exits

Nano Dimension and activist investor Murchison have reached an agreement to overhaul Nano's board of directors and the CEO position, leading to the departure of CEO Dave Stehlin and several directors. This move is aimed at aligning the company's strategy with shareholder interests and …

The Ensign Group, Inc. (ENSG) Stock Analysis: A Healthcare Leader Offering 27% Potential Upside

The Ensign Group, Inc. (ENSG) is a prominent healthcare provider with a $10.01 billion market cap, specializing in skilled nursing, senior living, and rehabilitative services. Analysts project a potential upside of 27.16% for ENSG, with an average target price of $217.80, driven by strong …

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics has restarted patient treatment in its Phase 2 INVINCIBLE-4 Study for triple-negative breast cancer (TNBC) in Switzerland, after a temporary pause to address skin irritation issues. The trial, using INT230-6 before standard-of-care immunotherapy-chemotherapy, aims to improve pathological complete response rates in patients …

Securities Fraud Investigation Into The Ensign Group, Inc. (ENSG)

Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into The Ensign Group, Inc. (ENSG) following reports alleging inadequate patient care and systematic misrepresentations. The investigation was prompted by a Hunterbrook Media report claiming Ensign's business model relies on delivering inadequate …

ETFs Investing in Ensign Group, Inc. Stocks

This article lists a comprehensive selection of Exchange Traded Funds (ETFs) that hold stocks of Ensign Group, Inc. It provides detailed financial metrics for each ETF, including market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year …

Nano Dimension ends headquarters lease, expects $25M net cash savings

Nano Dimension (NNDM) announced it has terminated its headquarters lease in Ness Ziona, Israel. The 3D printing company expects this move to result in approximately $25 million in net cash savings over the remaining seven-year lease period, including a $5.5 million one-time cash payment …

Nano Dimension (NASDAQ:NNDM) Shares Cross Below 50-Day Moving Average - Here's Why

Ensign Group (ENSG) director awarded 600 shares vesting over three years

Ann Scott Blouin, a director at Ensign Group, received a grant of 600 common stock shares on July 15, 2026. These shares, valued at $0.00 each, will vest in three equal annual installments starting July 15, 2027. This award increases her direct holdings to …

Ensign Group (ENSG) director Shaw granted 600 shares vesting from 2027

Ensign Group director Daren Shaw was granted 600 shares of common stock on July 15, 2026, as an award acquisition, which will vest in three equal annual installments starting July 15, 2027. This grant increases his direct holdings to 24,926 shares, with a reported …

Nano Dimension to End Lease on Current Headquarters

Nano Dimension Ltd. announced its intention to terminate the lease for its current headquarters and manufacturing facility complex in Ness Ziona, Israel. This strategic move aims to reduce overhead costs and simplify operations amidst its current corporate restructuring, with the lease scheduled to end …

Insider Sell: Mark Parkinson Sells Shares of Ensign Group Inc (E

Mark Parkinson, a Director at Ensign Group Inc (ENSG), sold 100 shares of the company on July 16, 2026, reducing his total holdings to 3,900 shares. This transaction is part of a trend for the company, which has seen 31 insider sells and 0 …

Form 4 The Ensign Group Inc For: 17 July By Investing.com

The article reports on a Form 4 filing for The Ensign Group Inc. for July 17. Form 4 is a U.S. Securities and Exchange Commission document which must be filed by company insiders to indicate a change in their ownership of the company's stock. …

Ensign Group (ticker: ENSG) grants director 600-share award

Ensign Group (ENSG) Director John O. Agwunobi was granted 600 shares of common stock on July 15, 2026, at a stated price of $0.00 per share. These shares will vest in three equal annual installments beginning July 15, 2027. Following this award, Agwunobi directly …

Truist Securities Maintains Ensign Group (ENSG) Hold Recommendation

This article from MSN is missing its content. It only provides a title indicating that Truist Securities has maintained a Hold recommendation for Ensign Group (ENSG).

Nano Dimension cuts costs by terminating HQ lease, saving $25M net through 2031

Nano Dimension (NNDM) has moved to terminate its corporate headquarters lease early, effective December 31, 2026, which was originally set to expire in 2031. This strategic decision is part of ongoing cost-saving efforts, initiated after the sale of MarkForged, Inc., to reduce cash burn …

Nano Flat on Terminating Lease

Nano Dimension Ltd. announced the termination of its corporate headquarters lease effective December 31, 2026. This move is part of ongoing cost-saving initiatives, negotiated to reduce future lease obligations substantially. The company anticipates cumulative net cash savings of approximately $25 million by eliminating about …

Nano Dimension terminates headquarters lease, cuts costs

Nano Dimension Ltd. announced the termination of its corporate headquarters lease effective December 31, 2026, a move expected to generate approximately $25 million in net cash savings by eliminating $38 million in future lease costs after a $13 million termination payment. This cost-cutting measure …

Nano Dimension Continues Execution of Cost Savings Initiatives

Nano Dimension announced it has reached an agreement to terminate the lease for its corporate headquarters, effective December 31, 2026. This action is expected to generate approximately $25 million in cumulative net cash savings by eliminating $38 million in future lease costs offset by …

Nano Dimension (NNDM) Moves to Cut Costs by Terminating Headquarters Lease

Nano Dimension (NNDM) is terminating its corporate headquarters lease effective December 31, 2026, to achieve significant cost savings. This strategic move is expected to save the company approximately $25 million in net cash after accounting for a termination fee. Despite potential undervaluation based on …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against The Ensign Group, Inc. (ENSG) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has announced an investigation into The Ensign Group, Inc. (ENSG) following two short reports by Hunterbrook and Muddy Waters Research. These reports allege inadequate patient care, understaffing, and potential Medicare/Medicaid fraud, leading to significant drops in ENSG's stock price. …

Is Sensient Technologies (SXT) Below Fair Value Following Its Recent Pullback?

Sensient Technologies (SXT) has experienced a recent share price pullback, but its longer-term performance remains strong. The stock is currently trading below a widely followed fair value estimate of $133, suggesting it may be undervalued, especially given the upcoming regulatory shift towards natural colors. …

[DFAN14A] Nano Dimension Ltd. SEC Filing

Murchinson Ltd., along with other participants

Nano Dimension | DFAN14A: Definitive additional proxy soliciting materials filed by non-management

This article reports that Nano Dimension has filed definitive additional proxy soliciting materials (DFAN14A) with the SEC. These materials were filed by non-management, indicating potential shareholder activism or a differing viewpoint from the current leadership regarding corporate governance or other matters ahead of a …

Nano Dimension (NNDM) Q3 2025 earnings summary

Nano Dimension (NNDM) reported Q3 2025 results with revenue up 81% year-over-year to $26.9M, primarily due to the Markforged acquisition, though standalone revenue decreased. The company appointed a new CFO, is undergoing a strategic alternatives review, and implemented significant cost reductions. They project Q4 …

Insider plans sale of 100 ENSG common shares in Form 144 filing (ENSG)

Mark Parkinson has filed a Form 144 notice to sell 100 common shares of ENSG stock through Fidelity Brokerage Services LLC, with a proposed sale date of July 16, 2026, for an aggregate value of $16,812. The shares vested as restricted stock on July …

Form 144 ENSIGN GROUP For: 16 July By Investing.com

This article announces the filing of Form 144 for ENSIGN GROUP (ENSG) on July 16, 2026, as reported by Investing.com. It is a brief administrative notice regarding market activity for the specified company. The content also briefly mentions other trending financial news and market …

Nano Dimension (NNDM) M&A announcement Summary

Nano Dimension (NNDM) announced a merger with Infinite Epigenetics, valuing Infinite Epigenetics at $890 million. This stock-for-stock deal creates a publicly traded, AI-powered preventive health and diagnostics company focused on early disease detection. The combined entity, expected to have over $400 million in cash, …

Kaplan Fox & Kilsheimer LLP Alerts The Ensign Group, Inc. (NASDAQ: ENSG) Investors to a Securities Investigation

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. (NASDAQ: ENSG) following a report from Hunterbrook Media alleging that Ensign's business model relies on inadequate patient care and "gaming data on quality." The report, titled “Ensign: The Nursing …

Intensity Therapeutics (INTS) AGM 2026 Summary

The Intensity Therapeutics (INTS) 2026 Annual General Meeting (AGM) was held virtually on June 16, 2026, at 10:30 AM ET. Key proposals included the re-election of two directors, ratification of EisnerAmper LLP as auditors, and amendments to the 2021 Stock Incentive Plan and 2024 …

Intensity Therapeutics (INTS) Q4 2025 earnings summary

Intensity Therapeutics (INTS) reported its Q4 2025 earnings, highlighting a cash balance of $11.9 million at year-end, providing a cash runway into Q2 2027. The company raised over $20 million in gross proceeds in 2025 and saw reduced R&D and G&A expenses, leading to …

ENSIGN INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is

Bragar Eagel & Squire, P.C. is investigating The Ensign Group, Inc. (NASDAQ:ENSG) on behalf of its stockholders. This investigation follows a short report alleging that Ensign Group's business model relies on inadequate patient care, gaming quality metrics, and understaffing, leading to patient suffering and …

ENSG Investor News: If You Have Suffered Losses in Ensign

The Rosen Law Firm is investigating potential securities claims against The Ensign Group, Inc. (NASDAQ: ENSG) following a short seller report alleging the company's business model relies on inadequate patient care and "gaming quality metrics." Investors who purchased Ensign securities and suffered losses are …

Intensity Therapeutics resumes patient dosing in Swiss trial

Intensity Therapeutics Inc. has resumed patient dosing in its INVINCIBLE-4 Study in Switzerland for early-stage, operable triple-negative breast cancer, following a temporary pause due to skin irritation. The company's stock has faced volatility, but analysts maintain a bullish outlook, with InvestingPro suggesting it is …

Intensity Therapeutics restarts 61-patient breast cancer trial

Intensity Therapeutics has restarted its INVINCIBLE-4 trial for breast cancer after pausing due to skin irritation. The company will now recruit an additional 47 patients in Switzerland and France using an amended single-injection protocol. Preliminary results from the first 14 patients show promising pathological …